PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-77.57%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-73.55%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-116.51%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-118.68%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-121.43%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-121.44%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-121.44%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-77.61%
Negative 10Y revenue/share CAGR while 4997.T stands at 38.27%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
50.02%
5Y revenue/share CAGR above 1.5x 4997.T's 14.24%. David Dodd would look for consistent product or market expansions fueling outperformance.
85.71%
3Y revenue/share CAGR above 1.5x 4997.T's 1.30%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
100.00%
10Y OCF/share CAGR in line with 4997.T's 100.00%. Walter Schloss would see both as similarly efficient over the decade.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
91.63%
Positive 10Y CAGR while 4997.T is negative. John Neff might see a substantial advantage in bottom-line trajectory.
-139.20%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
32.86%
Positive short-term CAGR while 4997.T is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
60.67%
5Y equity/share CAGR above 1.5x 4997.T's 40.30%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
36.59%
3Y equity/share CAGR above 1.5x 4997.T's 7.80%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.76%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
21.96%
Inventory growth well above 4997.T's 7.80%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-2.55%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-2.55%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
11.29%
Debt growth far above 4997.T's 5.15%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-81.04%
Our R&D shrinks while 4997.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-20.42%
We cut SG&A while 4997.T invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.